Statistics from Altmetric.com
Is osmotically released methylphenidate more effective than atomoxetine or placebo in children and adolescents with attention deficit hyperactivity disorder (ADHD)?
516 children and adolescents with DSM-IV ADHD (aged 6–16 years; 26% female, mean age 10.2 years). Exclusions: ADHD symptom severity <1.5 standard deviations above average on the ADHD Rating Scale IV-parent version; seizures, bipolar disorder, psychotic illness, anxiety and tic disorders, or pervasive developmental disorder; use of psychoactive medications; or experienced intolerable adverse events or no improvement when previously treated with study drugs.
20 sites, USA; time period not stated.
Osmotically released methylphenidate (n = 220; single morning dose of 18–54 mg/day), atomoxetine (n = 222; twice daily divided dose of 0.8–1.8 mg/kg/day) or placebo (n = 74) for 6 weeks. Washout of any psychoactive medication for at least 5 days was required prior to entry.
Response to …
Source of funding: Eli Lilly and Company, USA.
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.